Moderna's mRNA Cancer Vaccine Breakthrough: Biotech Stocks Poised for New Rally?

Moderna and Merck announced on August 19, 2026 that a personalized mRNA cancer vaccine achieved primary endpoints for the first time in a Phase 3 trial. Moderna's stock subsequently doubled during trading, reaching as high as $142.61 – a three-and-a-half-year high and the best trading day in the company's history.

First positive Phase 3 data for mRNA cancer therapy

The INTerpath-001 study tested a combination of personalized vaccine (Intismeran autogene, V940/mRNA-4157) and Merck's immunotherapy Keytruda in 1,137 patients with stage IIB to IV melanoma. The patients had previously undergone surgery. The vaccine encodes up to 34 tumor-specific targets, so-called neoantigens, which are customized based on each patient's individual tumor mutations.

Patients who received the vaccine in addition to Keytruda remained cancer-free longer than those treated with Keytruda alone. Additionally, the combination slowed the spread of cancer to distant organs. Earlier data from a mid-stage study phase showed a 49 percent reduction in recurrence or mortality risk over five years. Previously, no therapy had surpassed Keytruda in postoperative melanoma treatment.

No mRNA-based cancer therapy had previously completed a Phase 3 study with positive results. The safety profile was consistent with earlier investigations; no new risk signals emerged. Detailed efficacy data will be presented at a medical conference. Both companies plan to have discussions with regulatory authorities.

Moderna stock rises over 100 percent

Moderna stock (MRNA) opened on August 19, 2026 in pre-market trading at over $122, after closing at $62.96 on August 18. During the day, the price briefly reached $142.61, which represented a gain of 135 to 177 percent depending on the measurement time. Market capitalization thus stood at around $25 billion.

Since the start of 2026 through August 19, the stock's price gain totaled 357 percent. The August 19 rise was the largest single trading day in company history – according to market observers, \"by a large margin\". The stock had already more than doubled in value during the current year before the announcement, driven by a flu vaccine approval and pipeline progress.

By comparison, in August 2021, at the peak of the COVID-19 vaccine business, Moderna traded at over $480. Subsequently, the stock lost more than 90 percent of its value as demand for coronavirus vaccines declined.

Merck and biotech sector benefit

Merck stock (MRK) gained 6 to 9.3 percent on August 19, 2026. The smaller increase compared to Moderna reflects the fact that Keytruda is already an established blockbuster. The immunotherapy market is considered mature, so the market reaction was correspondingly more moderate.

Other biotech stocks also benefited: Novavax stock (NVAX) rose 6.4 percent on the same day, indicating positive sentiment for the sector as a whole.

Analysts remain cautious

William Blair upgraded Moderna to \"Outperform\" on August 19, 2026. However, the broader analyst community remained cautious: of 24 brokerages covering Moderna, 22 rated the stock as \"Hold\" or worse. The consensus price target was $55.12 – 55 percent below the intraday highs on August 19.

Short sellers came under pressure: 49.77 million shares were sold short, representing 13 percent of the float. On August 19, losses on these positions totaled around $4.8 billion. At average trading volume, short sellers would need more than six trading days to close their positions. Short interest had already declined 5 percent in the most recent reporting period before the announcement.

Options market and trading activity

On August 19, 2026, over 170,000 option contracts on Moderna changed hands – 19 times the average intraday volume. The most-traded contract was the August 120 call expiring on Friday. New positions were predominantly opened for purchase, indicating speculative interest.

Clinical context and next steps

Merck estimates that in the United States in 2026, approximately 112,000 new melanoma cases will be diagnosed and over 8,500 people will die from the disease. A personalized vaccine that reduces relapse rates could represent a significant therapeutic advance in this segment.

The complete efficacy data from the Phase 3 study are not yet available. The companies continue to collect survival data. Discussions with regulatory authorities regarding regulatory submissions are planned, but specific timelines were not provided.

Strategic significance for Moderna

The cancer vaccine success marks a strategic turning point for Moderna. Since the decline in COVID-19 vaccine demand, the company has attempted to expand its business model to broader platforms. The flu vaccine approval in early 2026 had already contributed to positive stock performance. The mRNA cancer vaccine now opens a potentially larger growth field.

Whether the stock gains are sustainable depends on regulatory approval, commercial viability, and pricing. The discrepancy between current price and analyst target points to significant valuation uncertainty.